Fabry disease is not a single, uniform condition. Two distinct presentations exist, and they can look so different from each other that patients and clinicians sometimes fail to recognise them as the same disease. Understanding the difference between classic Fabry disease and late-onset Fabry disease matters because the diagnostic path, the urgency of treatment, and the emotional experience of each are significantly different.

What Is the Difference Between Classic and Late-Onset Fabry Disease?

Classic Fabry disease begins in childhood and causes widespread organ involvement across the kidneys, heart, nervous system, and skin. Late-onset Fabry develops in adulthood and typically affects one or two organs, most commonly the heart or kidneys. Both types are caused by mutations in the GLA gene but differ in the amount of residual enzyme activity the body retains.

Both classic and late-onset Fabry disease are caused by mutations in the GLA gene, which disrupts the production of an enzyme called alpha-galactosidase A (alpha-Gal A). Without enough of this enzyme, a fatty substance called GL-3 accumulates inside cells and causes progressive damage to organs throughout the body.

The key difference lies in how much residual enzyme activity a person retains. In classic Fabry disease, enzyme activity is typically less than 1 per cent of normal. In late-onset Fabry, patients retain between 2 and 30 per cent of normal enzyme activity. This partial function significantly changes when and how the disease appears.

Classic Fabry Disease

Classic Fabry disease begins in childhood, usually between ages 3 and 10, and causes symptoms across multiple organ systems simultaneously. It is associated with very low or absent alpha-Gal A enzyme activity and, without treatment, significantly shortens life expectancy.

When Symptoms Begin

Children with classic Fabry disease typically develop their first symptoms between the ages of 3 and 10. The earliest and most defining symptom is neuropathic pain, a burning or stabbing sensation in the hands and feet that can be constant or episodic. These children are often told they have growing pains, anxiety, or nothing at all. Many spend their entire childhoods in pain that no one believes.

The Full Symptom Picture

Classic Fabry disease involves multiple organ systems from an early age. As well as neuropathic pain, children and teenagers with classic Fabry disease often experience an inability to sweat normally (making exercise and heat dangerous), gastrointestinal symptoms including cramping and diarrhoea, small dark raised spots on the skin called angiokeratomas, and a distinctive whorl-like pattern on the cornea called cornea verticillata, which does not affect vision but is a useful diagnostic clue.

Over time, without treatment, classic Fabry disease causes progressive kidney failure, cardiac thickening, stroke, and significantly shortened life expectancy. The average reduction in life expectancy in untreated classic male patients has historically been 15 to 20 years.

The Diagnostic Delay Problem

Despite beginning in childhood, classic Fabry disease takes an average of 10 to 16 years to diagnose. By the time a correct diagnosis is made, many patients have experienced organ damage that earlier treatment could have slowed or prevented. Raising awareness of classic Fabry symptoms in children and teenagers is one of the most important contributions patient education can make.

Late-Onset Fabry Disease

Late-onset Fabry disease develops in adulthood, typically in the 30s to 60s. It usually affects one or two organs rather than the whole body, with the heart and kidneys most commonly involved. It represents approximately 60 to 70 per cent of all Fabry diagnoses and remains massively underdiagnosed.

Who Gets Late-Onset Fabry

Late-onset Fabry occurs when a GLA mutation leaves the body with some residual enzyme activity, typically between 2 and 30 per cent of normal. This partial function delays the disease significantly and often limits its impact to one or two organs rather than causing the widespread damage seen in classic Fabry.

Late-onset Fabry most commonly presents as unexplained thickening of the heart muscle (left ventricular hypertrophy) or progressive kidney disease in adults who had no symptoms in childhood. Many patients are diagnosed only after being investigated for an apparently unrelated cardiac or renal problem.

The Hidden Scale of Late-Onset Fabry

Late-onset Fabry disease is estimated to represent 60 to 70 per cent of all Fabry diagnoses. Despite this, it remains one of the most underdiagnosed conditions in cardiology and nephrology. Research suggests that approximately 1 to 4 per cent of patients with unexplained left ventricular hypertrophy may have undiagnosed Fabry disease. If you or a family member has been told they have an unexplained thickened heart muscle, Fabry disease is worth discussing with a specialist.

Why Late-Onset Fabry Is Missed

Late-onset Fabry disease is routinely missed for several reasons. First, it does not follow the textbook picture of a childhood-onset, multi-organ disease. A cardiologist investigating unexplained left ventricular hypertrophy in a 55-year-old patient may not think to test for a rare genetic condition. Second, unlike classic Fabry, late-onset patients often have no history of neuropathic pain, no angiokeratomas, and no other visible signs of the disease outside of their presenting organ involvement. Third, awareness of Fabry disease among adult cardiologists and nephrologists remains low.

How Classic and Late-Onset Fabry Are Diagnosed

Classic Fabry in males is confirmed by an enzyme assay measuring alpha-Gal A activity. Late-onset Fabry may return borderline enzyme results and often requires GLA genetic testing to confirm. In women, genetic testing is always required regardless of enzyme results.

In males with classic Fabry disease, the enzyme assay typically returns a very low or undetectable alpha-Gal A result, making the diagnosis straightforward once the test is ordered. The challenge is persuading a clinician to order the test in the first place.

In late-onset Fabry, particularly in males with some residual enzyme activity, results can be borderline and easy to dismiss. In these cases, or whenever the clinical picture is suggestive of Fabry but the enzyme result is not definitive, GLA genetic testing should be performed. In women, genetic testing is always required regardless of enzyme levels.

Does Treatment Differ Between Classic and Late-Onset Fabry?

The available treatments, enzyme replacement therapy and migalastat, are the same for both classic and late-onset Fabry. The timing and urgency of treatment may differ: classic Fabry typically warrants treatment as soon as diagnosis is confirmed, while late-onset treatment decisions are guided by organ involvement and progression.

Enzyme replacement therapy provides the body with the missing alpha-Gal A enzyme via intravenous infusion every two weeks. Migalastat is an oral medication taken every other day and is suitable only for patients with specific GLA mutations (approximately 35 to 50 per cent of known mutations). A treating specialist will determine which treatment is appropriate based on mutation type, age, organ involvement, and clinical progression.

For patients with late-onset Fabry who have limited organ involvement at the time of diagnosis, the treating team may monitor closely before initiating treatment. This decision should be made in partnership between the patient and a specialist with Fabry disease experience, not deferred indefinitely.